We Didn't Fail to Stop Ebola Bundibugyo — We Chose Not to Make the Vaccine for 19 Years
The 2026 Bundibugyo Ebola outbreak in the Democratic Republic of Congo has reignited urgent questions about the structural inequities embedded in the global health system. Bundibugyo ebolavirus (BDBV), first identified in Uganda in 2007, has claimed lives for nearly two decades without a single approved vaccine — a stark contrast to the COVID-19 pandemic, during which the world developed and deployed mRNA vaccines within nine months. The WHO's unprecedented decision to declare a Public Health Emergency of International Concern (PHEIC) without convening an emergency committee underscores the severity of the crisis while simultaneously exposing the system's failure to prepare for so-called "neglected" outbreaks. The Trump administration's USAID funding cuts created a nine-day surveillance blind spot after the WHO notified the United States of the outbreak, directly undermining early containment efforts. This outbreak is not a natural disaster — it is the product of decades of deliberate underinvestment shaped by pharmaceutical market logic, and it demands a reckoning with who gets to decide which lives are worth protecting.